Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted
Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.
No chemotherapy, radiotherapy, major surgery, or biologic therapy within  weeks of protocol treatment
Prior treatment: chemotherapy or radiotherapy or surgery
History of receiving chemotherapy or radiotherapy
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within  weeks before registration; patients who received prior radiotherapy to >= % of bone marrow are not eligible independent of when it was received
Patient received radiotherapy, surgery, chemotherapy, or an investigational therapy within  weeks prior to study entry
localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy;
Any prior chemotherapy, surgery, or radiotherapy for EAC
If a cancer survivor, the patient received prior systemic chemotherapy or radiotherapy
Patients who have had prior chemotherapy or radiotherapy for the treatment of pancreas cancer
Prior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancer
Within  days of completion of standard therapy (surgery, chemotherapy  radiotherapy)
No prior chemotherapy or radiotherapy for this malignancy
Patients must not have received prior chemotherapy, radiotherapy, or antibody therapy for lymphoma
Patients who have received any radiotherapy or chemotherapy for their current gynecological cancer
Prior chemotherapy, radiotherapy, biological cancer therapy or major surgery within  days prior to enrollment
Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.
Any treatment, including radiotherapy, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry.
The patient has received therapeutic dose chemotherapy or radiotherapy ?  days prior to start of Investigational Product.
No previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.
No prior chemotherapy, radiotherapy, or antiangiogenic therapy
Prior chemotherapy or radiotherapy
Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within  week of treatment day 
Patient must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease.
Patients may have had prior therapy, including radiotherapy (systemic and/or cranial and/or spinal) or chemotherapy; at least  days must have elapsed since completion of radiotherapy and  days since completion of prior chemotherapy ( days for nitrosourea chemotherapy)
No chemotherapy, radiotherapy, major surgery, or biologic therapy within  weeks of protocol treatment
Concurrent cancer chemotherapy, radiotherapy or surgery
Received monoclonal antibodies (for any reason), chemotherapy, surgery, investigational therapy, or radiotherapy within  days of the first dose of mogamulizumab;
Received radiotherapy and temozolomide chemotherapy
At least  days since localized surgery, radiotherapy or chemotherapy
All adverse events of any prior chemotherapy, surgery, or radiotherapy not resolved
Major surgery, radiotherapy, chemotherapy or investigational agents within four weeks of treatment day 
Prior chemotherapy or radiotherapy for any brain tumor
PATIENT ONLY: Patients must be within  month of initiating or having undergone any type of cancer treatment (i.e., surgery, radiotherapy, chemotherapy)
Diagnosis of cancer (any stage) for which active treatment (e.g., surgery, chemotherapy, and/or radiotherapy) has been completed within  months to  years
Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer
Prior chemotherapy for SCCHN and/or radiotherapy to the region of the study cancer or
Prior chemotherapy or radiotherapy
Prior cancer chemotherapy or radiotherapy
Patients who have received surgery alone or radiotherapy alone as definitive local therapy
Women who have received cancer surgery, chemotherapy, biological therapy (e.g., trastuzumab), or radiotherapy for the treatment of any cancer within  months of study participation
Patient has received prior chemotherapy or radiotherapy for this cancer
Prior chemotherapy or radiotherapy within the last three years
Patient has received prior chemotherapy or radiotherapy for this cancer